This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2016
  • /
  • 06
  • /
  • FDA gives 510(k) approval for Elecsys BRAHMS PCT (...
Drug news

FDA gives 510(k) approval for Elecsys BRAHMS PCT (procalcitonin) assay in sepsis detection- Roche

Read time: 1 mins
Last updated:24th Jun 2016
Published:24th Jun 2016
Source: Pharmawand

Roche has received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing solution for people with severe sepsis or septic shock. With this clearance, Roche is the first IVD company in the U.S to provide a fully integrated solution for sepsis risk assessment and management.

The clearance of Roche's PCT solution is a result of the U.S. multicenter Procalcitonin Monitoring Sepsis Study (MOSES). The novel trial design of Thermo Fisher Scientific's MOSES study leveraged the same patient samples to enable a "universal analysis" approach to demonstrate substantial equivalence to the FDA resulting in the clearance of the Elecsys BRAHMS PCT assay.

Comment: The Elecsys BRAHMS PCT assay is designed to provide full automation, which means no reagent preparation or hands-on testing is required. This assay offers same-day testing capability with an incubation time of only 18 minutes.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.